Pay in 4 interest-free payments of $5.54 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Aterini S, Ciciani AM, Bergesio F et al (2022) Intradialytic hypotension frequency is reduced by levocarnitine supplementation
Wij kiezen bewust voor betrouwbare leveranciers en duidelijke productinformatie, zodat onderzoekers beschikken over hoogwaardige onderzoeksmaterialen
23, Novo executives said CagriSema still has the potential to deliver the highest weight loss of any drug on the market after its expected approval by the Food and Drug Administration by the end of 2026 and launch in 2027
Obstetrics Gynecology
Oily skin also gets dried up
Benefits of lixilan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: the LixiLan-O randomized trial
US$ 27.20
US$ 29.88
US$ 24.64
US$ 28.85
